Premium
European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL ‐4 (2011)
Author(s) -
MatthesMartin S.,
Feuchtinger T.,
Shaw P.J.,
Engelhard D.,
Hirsch H.H.,
Cordonnier C.,
Ljungman P.
Publication year - 2012
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12022
Subject(s) - cidofovir , medicine , transplantation , hematopoietic stem cell transplantation , stem cell , immunology , leukemia , disease , cord blood , polymerase chain reaction , graft versus host disease , virus , biology , biochemistry , gene , genetics
Human adenovirus ( HA dV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T‐cell function. The 4th E uropean C onference of I nfections in L eukemia ( ECIL ‐4) has developed evidence‐based guidelines for diagnosis and management of HA dV infections. The risk for HA dV‐associated disease is increased in children, and risk factors for HA dV disease are T‐cell depletion, unrelated and cord blood hematopoietic stem cell transplantation, graft‐versus‐host disease grades III–IV, and lymphopenia. The recommended technique for monitoring of high‐risk patients is quantitative polymerase chain reaction. Cidofovir is the most used antiviral therapy, although no controlled study has been performed. HAdV‐specific T‐cell therapy is in development.